We hypothesize that TGF-β pathway activation is common in pancreatic cancer and genetic variations of the pathway, plasma TGF-β1 level and tumor TGF-βR2 or SMAD4 expression are associated with clinical outcome of pancreatic cancer. This evidence concerns the gene TGFB1 and familial pancreatic carcinoma.